Chronic smell and flavor loss treatment sales will expand through 2036, with smell disorder holding a 57.3% share of the classification segment in 2026. Anosmia or hyposmia leads the segment with a 48.9% share. The market is set to reach USD 3.8 billion by 2026-end and USD 6.9 billion by 2036.